2m 2m 2m 2m 2m 2m 2m
Theravance Bioph (TBPH)
NASDAQ
$15.89+$0.31 (+1.99%)
Price as of Jun 03, 2026 4:10 PM EDT- $1.2BMarket Cap
- 40.11%1-Year Change
- BiotechnologyIndustry
Theravance Bioph (TBPH)
$15.89+$0.31 (+1.99%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 75.0M +16.44% | 64.4M +12.12% | 57.4M +11.84% | 51.3M -7.17% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 75.0M +16.44% | 64.4M +12.12% | 57.4M +11.84% | 51.3M -7.17% | |
Sales and Marketing Expense | 73.7M +6.47% | 69.2M -1.31% | 70.1M +4.51% | 67.1M -32.45% | |
Research and Development Expense | -37.4M -0.61% | -37.6M -7.33% | -40.6M -35.92% | -63.4M -67.27% | |
Depreciation and Amortization Expense | 1.6M -4.91% | 1.7M -14.54% | 2.0M -46.15% | 3.7M -37.14% | |
Total Operating Expenses | 111.1M -0.24% | 111.3M -1.88% | 113.5M -20.83% | 143.3M -54.23% | |
Operating Profit | -3.6M -92.33% | -46.9M -16.21% | -56.0M -39.06% | -92.0M -64.33% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | -2.4M -63.10% | -6.4M -86.42% | |
Interest Income and Expense and Net | 0 N/A | 0 +100.00% | -2.4M -63.10% | -6.4M -86.42% | |
Total Nonoperating Income and Expense | 10.2M +108.42% | 4.9M -46.46% | 9.1M +6.68% | 8.5M +670.51% | |
Income before Taxes | 129.2M +389.70% | -44.6M -9.45% | -49.3M -46.92% | -92.8M -53.49% | |
Income Taxes | 23.4M +97.83% | 11.8M +99.26% | 5.9M +65,722.22% | 9,000 +105.96% | |
Extraordinary Items | 0 N/A | 0 N/A | N/A N/A | N/A N/A | |
Net Income | 105.9M +287.70% | -56.4M +2.22% | -55.2M -106.33% | 872.1M +537.32% | |
Net Income from Continuing Operations Applicable to Common | 129.2M +389.70% | -44.6M -19.17% | -55.2M -40.54% | -92.8M -53.49% | |
Basic EPS and Net Income | 2.10 +282.61% | -1.15 +15.00% | -1.00 -108.44% | 11.85 +512.89% | |
Diluted EPS and Net Income | 2.06 +279.13% | -1.15 +15.00% | -1.00 -108.44% | 11.85 +512.89% | |
Basic Weighted Average Shares | 50.3M +3.01% | 48.8M -11.67% | 55.3M -24.85% | 73.6M +5.95% | |
Diluted Weighted Average Shares | 51.5M +5.45% | 48.8M -11.67% | 55.3M -24.85% | 73.6M +5.95% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 167.8M +343.97% | 37.8M -4.42% | 39.5M -86.74% | 298.2M +231.45% | |
Short-Term Investments | 147.6M +191.87% | 50.6M -19.61% | 62.9M +114.52% | 29.3M -64.90% | |
Cash and Cash Equivalents and Short-Term Investments | 315.4M +256.94% | 88.3M -13.74% | 102.4M -68.72% | 327.5M +88.79% | |
Total Current Assets | 418.5M +159.80% | 161.1M +20.61% | 133.5M -62.22% | 353.5M +41.46% | |
Accumulated Depreciation | 23.8M +6.34% | 22.4M +3.79% | 21.6M -34.27% | 32.8M -14.69% | |
Property and Plant and Equipment and Net | 5.9M -20.53% | 7.4M -18.20% | 9.1M -23.64% | 11.9M -13.05% | |
Total Long-Term Assets | 24.9M +102.51% | 12.3M +52.30% | 8.1M +16.93% | 6.9M +113.72% | |
Total Assets | 485.6M +37.10% | 354.2M -7.29% | 382.0M -37.11% | 607.4M +62.05% | |
Income Taxes Payable | 5.3M -9.67% | 5.9M N/A | N/A N/A | 252,000 N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 38.3M +19.38% | 32.1M +29.55% | 24.8M -13.75% | 28.7M -50.99% | |
Total Long-Term Debt | N/A N/A | N/A N/A | 0 -100.00% | 228.0M 0.00% | |
Total Long-Term Liabilities | 313,000 -83.44% | 1.9M -68.07% | 5.9M +257.21% | 1.7M -31.53% | |
Total Liabilities | 70.1M -1.59% | 71.2M +1.70% | 70.0M -5.56% | 74.1M -33.38% | |
Retained Earnings | -859.6M -10.97% | -965.5M +6.21% | -909.1M +6.46% | -853.9M -50.53% | |
Total Stockholders Equity | 296.7M +69.03% | 175.5M -17.58% | 213.0M -51.79% | 441.8M +230.49% | |
Total Shares Outstanding | 51.1M +3.23% | 49.5M +2.87% | 48.1M -26.27% | 65.2M -12.37% | |
Cash Flow | |||||
Cash from Operating Activities | 238.5M +2,167.98% | -11.5M -57.27% | -27.0M -85.56% | -187.0M -10.04% | |
Capital Expenditures | 42,000 -87.35% | 332,000 -86.66% | 2.5M +334.97% | 572,000 -83.21% | |
Cash from Investing Activities | -105.3M -957.08% | 12.3M +137.57% | -32.7M -102.83% | 1.2B +826.96% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -3.2M +30.08% | -2.5M -98.74% | -198.9M -73.78% | -758.8M -926.05% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -4.80% -93.41% | -72.92% -25.27% | -97.58% -45.51% | -179.09% -61.57% | |
Return on Assets | 25.22% +264.55% | -15.33% +37.38% | -11.16% -106.28% | 177.58% +475.73% | |
Return on Equity | 44.85% +254.42% | -29.04% +72.27% | -16.86% -101.00% | 1,689.74% +2,621.21% | |
Revenue Growth | 16.44% +35.68% | 12.12% +2.35% | 11.84% +265.13% | -7.17% -68.87% | |
Current Ratio | 10.93 +117.64% | 5.02 -6.90% | 5.39 -56.20% | 12.31 +188.62% | |
Cash Ratio | 4.38 +271.91% | 1.18 -26.22% | 1.60 -84.62% | 10.38 +576.25% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow